[ad#PhycoBiosciences AIM Interview]

Innovations

Sealantis’ alga-mimetic sealant in clinical study

July 22, 2013
AlgaeIndustryMagazine.com

Seal-1

Haifa, Israel-based Sealantis Ltd., a private start-up emerging from the Technion-Israel Institute of Technology, reports that eight patients have now been treated with Seal-V, its alga-mimetic vascular sealant, as part of the company’s first clinical study.

Seal-V is a protein-free sealant, designed to resolve current limitations and challenges in the control of surgical bleeding. The clinical trial, taking place in Israel, is evaluating the safety and efficacy of achieving hemostasis in large peripheral blood vessels using the Seal-V protein-free sealant.

Sealantis is a 6-year-old startup, located on the campus of one of Israel’s leading academic centers — the Technion. Sealantis was founded by Prof. Havazelet Bianco-Peled, a world-renowned expert in biomedical polymers.

Since the early 2000s, Prof. Bianco-Peled had been researching the adhesion mechanism of algae to rocks underwater. The research unveiled the chemical composition of the algae adhesive, but it was the professor’s invention of a synthetic, alga-mimetic adhesive that enabled harnessing nature’s power for practical and commercial uses.

Seal-2

In 2007, the invention was embraced by the Alfred Mann Institute at the Technion (AMIT), which is funding the company. While having potential uses in a variety of industrial applications, Sealantis chose to focus on urgent medical needs –  controlling leakage of body fluids through surgical or traumatic wounds. Such leaks can be fatal since sutures or staples are not fully leak-proof. “Sealing surgical incisions requires sticking to wet or moist surfaces, which is a challenge that most known adhesives can’t usually meet,” said Prof. Bianco-Peled.

Surgical sealants represent a market of over $1.0 billion, which grows 14% annually. “When I look at the market, it’s clear to me that there is no single winning solution,” says Dr. Zeev Gilkis, AMIT CEO and Sealantis Ltd. Chairman. “There are some good products, but each one has drawbacks or is limited to a specific application. Sealantis brings a versatile yet simple technology, addressing unmet clinical needs.”

“Seal-V is overcoming a clinical need with its unique features, which offer simultaneous sealing and hemostasis for native and synthetic vascular fields,” said Prof. Vincent Riambau, Chief of Vascular Surgery Division, Hospital Clínic, University of Barcelona, and Past President of the European Society of Vascular Surgery (ESVS), who serves on the Clinical Advisory Board of Sealantis. “It is accomplishing valuable qualities for vascular surgery, being quick, easy to use, effective and safe. It will surely be most welcome to the vascular community.”

Sealantis Ltd. is currently planning its next regulatory steps toward a PMA study and FDA approval of Seal-V and is working on strategic partnerships towards the coming market launch.”

More Like This…

HOME Algae Industry Jobs

Copyright ©2010-2013 AlgaeIndustryMagazine.com. All rights reserved. Permission granted to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

From The A.I.M. Archives

— Refresh Page for More Choices
James “Jamie” Levine took over the reigns at Sapphire Energy in July of this year as former President and CEO Cynthia “CJ” Warner stepped down, retaining her role as chai...
William Tucker writes in fullfreedom.org about the lure the oceans have for advocates of biofuel, particularly in Scandinavia. “Two-thirds of the globe is covered with wa...
As one of the most water-poor countries in the world, Jordan’s current water resources are significantly below the global water scarcity line. Annual rainfall falls under...
None of us would be alive if sperm cells didn’t know how to swim, or if the cilia in our lungs couldn’t prevent fluid buildup. But we know very little about the dynamics ...
Rich McEachran writes in the Guardian that, in the process of surfacing a road, layers of asphalt – which is composed mostly of bitumen (a byproduct of crude oil distilla...
The fully automated plant at the Fraunhofer Center for Chemical-Biotechnological Processes CBP in Leuna, Germany, was designed to produce microalgae at industrial scale. ...
Algiran, an Iranian algal biotech company, has recently established a pilot scale algal cultivation demonstration facility at the Chabahar Free Zone, in the Baluchistan P...
Michigan State University (MSU) and PHYCO2, an algae growth and CO2 sequestration company based in Santa Maria, CA, have entered into a partnership to develop algae techn...
Bloomberg reports that ANA Holdings Inc., Japan’s largest airline, plans to use a Euglena Co. biofuel made from algae. ANA will use a mix of about 10 percent of the algae...
CleanMalaysia.com reports that rooftop spirulina gardens are part of a burgeoning do-it-yourself urban farm project in Bangkok, Thailand’s capital. They are aimed at grow...
The GNT Group, a market leader in using algae as natural ingredients for color, has begun construction of an additional spirulina plant at its headquarters in Mierlo, the...
San Francisco biotech startup New Wave Foods aims to address the impact of overfishing, bycatch, water pollution, slave labor, an animal death toll in the trillions, and ...